Stephens reiterated their buy rating on shares of Glaukos Corporation (NYSE:GKOS) in a research report released on Friday morning. They currently have a $47.00 target price on the medical instruments supplier’s stock.

GKOS has been the topic of a number of other research reports. BidaskClub lowered shares of Glaukos Corporation from a hold rating to a sell rating in a research note on Saturday, August 26th. Zacks Investment Research upgraded shares of Glaukos Corporation from a hold rating to a strong-buy rating and set a $48.00 price objective on the stock in a research note on Tuesday, July 4th. Roth Capital cut their price objective on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating on the stock in a research note on Thursday, August 3rd. Stifel Nicolaus reiterated a buy rating on shares of Glaukos Corporation in a research note on Thursday, September 14th. Finally, BMO Capital Markets reiterated a buy rating and issued a $54.00 price objective on shares of Glaukos Corporation in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Glaukos Corporation currently has an average rating of Buy and an average price target of $49.86.

Shares of Glaukos Corporation (NYSE GKOS) opened at 32.16 on Friday. The stock’s 50 day moving average is $36.92 and its 200-day moving average is $38.03. Glaukos Corporation has a 12 month low of $28.72 and a 12 month high of $52.49. The company’s market cap is $1.11 billion.

TRADEMARK VIOLATION NOTICE: “Glaukos Corporation’s (GKOS) Buy Rating Reaffirmed at Stephens” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/19/glaukos-corporations-gkos-buy-rating-reaffirmed-at-stephens.html.

In related news, CEO Thomas William Burns sold 73,788 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc sold 580,200 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. Insiders sold 980,200 shares of company stock worth $37,900,263 in the last quarter. Company insiders own 16.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Navellier & Associates Inc grew its position in Glaukos Corporation by 4.9% during the second quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock valued at $1,381,000 after buying an additional 1,567 shares during the period. Public Employees Retirement System of Ohio grew its position in Glaukos Corporation by 14.5% during the second quarter. Public Employees Retirement System of Ohio now owns 118,100 shares of the medical instruments supplier’s stock valued at $4,898,000 after buying an additional 15,000 shares during the period. Koch Industries Inc. acquired a new stake in Glaukos Corporation during the second quarter valued at $683,000. Ameritas Investment Partners Inc. grew its position in Glaukos Corporation by 93.1% during the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,212 shares during the period. Finally, California State Teachers Retirement System grew its position in Glaukos Corporation by 54.0% during the second quarter. California State Teachers Retirement System now owns 50,752 shares of the medical instruments supplier’s stock valued at $2,105,000 after buying an additional 17,800 shares during the period.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.